Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate

@article{Stahl2018BeyondTD,
  title={Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate},
  author={Stephen M Stahl},
  journal={CNS Spectrums},
  year={2018},
  volume={23},
  pages={187 - 191}
}
  • S. Stahl
  • Published 1 June 2018
  • Psychology
  • CNS Spectrums
Psychosis is now widely hypothesized to involve neural networks beyond the classical dopaminergic mesolimbic pathway, including serotonin and glutamate systems as well. 
New hope for Alzheimer’s dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis
More than a decade of failure to find disease-modifying treatments for Alzheimer’s dementia has driven the field back to finding better symptomatic treatments for behavioral symptoms of dementia,
Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment
TLDR
The evidence for the role of endogenous oxytocin in schizophrenia is highlighted, from animal models to human studies, and the potential of oxytocIn as a therapeutic agent for schizophrenia and its implication in future treatment is discussed.
Relevance of 5-HT2A Receptor Modulation of Pyramidal Cell Excitability for Dementia-Related Psychosis: Implications for Pharmacotherapy
TLDR
A literature review was conducted to identify mechanisms that explain the role of 5-HT2ARs in both the etiology and treatment of dementia-related psychosis and why suppressing 5- HT2AR activity could be an effective strategy to treat dementia- related psychosis.
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction
TLDR
Although the pathophysiology and mechanisms of oxytocinergic dysfunction in metabolic syndrome and schizophrenia are both complex and it is still too early to draw a conclusion upon, oxytoc inergic dysfunction may yield a new mechanistic insight into schizophrenia pathogenesis and treatment.
Are CB2 Receptors a New Target for Schizophrenia Treatment?
TLDR
Studies describing the involvement of the CB2 receptor in these processes and their association with the pathophysiology of schizophrenia are reviewed to indicate that CB2 receptors may emerge as a new target for the development of antipsychotic drugs.
Vortioxetine improved social and cognitive deficits in acute ketamine model of schizophrenia in rats
TLDR
Vortioxetine may have beneficial effects, especially on negative symptoms of schizophrenia, and it will be beneficial to confirm this study in different schizophrenia models of rodents and investigating the possible underlying mechanism.
Dementia-related psychosis and the potential role for pimavanserin
TLDR
Pimavanserin, an atypical antipsychotic, is a selective serotonin inverse agonist/antagonist at 5-HT2A receptors that may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function.
Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets
TLDR
This review discusses the newest insights into the pathophysiology of and risk factors for schizophrenia and notes novel approaches in antipsychotic treatment and potential diagnostic and theranostic biomarkers.
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
  • F. Gomes, A. Grace
  • Psychology, Medicine
    International journal of molecular sciences
  • 2021
TLDR
Treatment of schizophrenia (SCZ) historically relies on the use of antipsychotic drugs to treat psychosis, but all of the currently available antipsychotics acting through the antagonism of dopamine D2 receptors are not effective against negative and cognitive symptoms.
...
...

References

SHOWING 1-10 OF 16 REFERENCES
Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome
  • S. Stahl
  • Psychology, Medicine
    CNS Spectrums
  • 2016
Parkinson’s disease psychosis (PDP) is theoretically a serotonin-dopamine imbalance syndrome due to disruption of the normal balance between the serotonergic and dopaminergic neurotransmitter systems
Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?
TLDR
It is suggested that if there may be common neurobiological pathways between the different pharmacological systems that are responsible for the hallucinations, there may also be unique properties of each system, which explains the clinical differences observed.
Stahl's essential psychopharmacology : neuroscientific basis and practical application
TLDR
The fourth edition CME information about chemical neurotransmission, receptors and enzymes as targets of psychopharmacological drug action, and its implications for treatment of mood disorders, anxiety disorders and anxiolytics is presented.
Serotonin 2A receptors and visual hallucinations in Parkinson disease.
TLDR
This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD, and treatment studies should be performed using selective serotonin2A receptor antagonists.
Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations
  • P. Huot, T. H. Johnston, S. Fox
  • Biology, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2010
TLDR
New insights are provided into the pathophysiology of VH in PD and an anatomical basis is provided to explain why compounds with 5‐HT2A antagonist activity are effective at alleviating this debilitating complication.
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
  • B. Ravina, K. Marder, C. Goetz
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2007
TLDR
It is suggested that PDPsy may result from progression of the disease process underlying PD, rather than a comorbid psychiatric disorder or drug intoxication, and are a potential indication for therapy development.
The changing face of Parkinson's disease‐associated psychosis: A cross‐sectional study based on the new NINDS‐NIMH criteria
TLDR
The findings suggest that the epidemiology of PDAP should be re‐evaluated with the new criteria and that minor symptoms and nonvisual hallucinations are an important part of the PDAP spectrum, which has commonly been restricted to visual hallucinations and delusions.
Neural correlates of the LSD experience revealed by multimodal neuroimaging
TLDR
Three complementary neuroimaging techniques, implemented during resting state conditions, revealed marked changes in brain activity after LSD that correlated strongly with its characteristic psychological effects, contributing important new insights into the characteristic hallucinatory and consciousness-altering properties of psychedelics.
Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants.
TLDR
A high proportion of both cocaine- and methamphetamine- dependent men and women reported delusions of paranoia and auditory hallucinations, however, during the abstinent and intoxicated conditions, methamphetamine-dependent men andWomen were more likely than cocaine-dependentMen and women to report psychotic symptoms.
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
TLDR
When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences that, at 14-month follow-up, were considered by volunteers to be among the most personally meaningful and spiritually significant of their lives.
...
...